ADRB3 and leukemia: Interestingly, β3-AR expression has been reported also in human leukemia (28) where it appears to be involved in the survival of myeloid leukemia cells, especially under hypoxic conditions, to such an extent that β3-AR could be considered as a potential target also in this type of cancer, mostly to reduce chemoresistance, a phenomenon that occurs frequently in leukemic patients (29).